logo

BALPHARMA vs GRANULES: Stock Comparison

BALPHARMA vs GRANULES INDIAUpdated 5 Oct 26, 4:08 PM ISTNSE & company filings

GRANULES INDIA is the larger company by market capitalisation. BALPHARMA shows a higher dividend yield, while GRANULES INDIA shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

BALPHARMA leads 1; GRANULES leads 7 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

BALPHARMAGRANULES

Valuation lens

What price are you paying?

Market CapContext only
₹134 Cr
₹22,358 Cr
P/E RatioSame reading
—
30.39x
P/B RatioSame reading
—
3.99x
EPSGRANULES has the higher reading
₹0.71
₹7.26 ✓
Book ValueContext only
₹51.66
₹205.21
Dividend YieldBALPHARMA has the higher reading
1.36% ✓
0.22%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
GRANULES is the larger company
₹22,358 Cr vs ₹134 Cr
EPS
GRANULES has higher earnings per share
₹7.26 vs ₹0.71
Dividend Yield
BALPHARMA has a higher dividend yield
1.36% vs 0.22%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs 2.7%
EPS Growth (TTM YoY)
GRANULES has faster EPS growth
31.3% vs -33.5%
ROE
GRANULES has a higher ROE
9.11% vs 6.49%
Net Margin
GRANULES has a higher net margin
11.15% vs 2.02%
Operating Margin
GRANULES has a higher operating margin
17.19% vs 7.46%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBALPHARMAGRANULES
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBALPHARMAGRANULES
Live Price₹106.79₹817
Day Change0.99%1.16%
Volume25,5225.12 L
52-Week High₹124.6₹923.65
52-Week Low₹60₹529.85
Distance from 52W High-14.29%-11.55%

Valuation

MetricBALPHARMAGRANULES
Market Cap₹134 Cr₹22,358 Cr
P/E Ratio—30.39x
P/B Ratio—3.99x
EPS₹0.71₹7.26
Book Value₹51.66₹205.21
Dividend Yield1.36%0.22%

Growth

MetricBALPHARMAGRANULES
Revenue Growth (TTM YoY)2.7%22.8%
EPS Growth (TTM YoY)-33.5%31.3%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricBALPHARMAGRANULES
ROE6.49%9.11%
ROCE9.07%9.07%
Net Margin2.02%11.15%
Operating Margin7.46%17.19%
Debt to Equity1.48x0.17x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricBALPHARMAGRANULES
Promoter Holding46.74%37.08%▼ 0.59 pp
FII Holding0.28%▲ 0.13 pp20.25%▲ 2.75 pp
DII Holding0%15.33%▼ 0.78 pp
Public Holding48.87%▼ 0.12 pp27.04%▼ 1.34 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALPHARMA and GRANULES INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.